OUR FOCUS
WHAT WE DO
Increasing pressure on healthcare systems highlight the need for new innovative approaches to disease prevention and treatment. We are developing new technologies to enable shorter development cycles and large scale manufacturability and increase the accessibility, affordability, durability, specificity, safety and effectiveness of immunotherapies for millions of patients worldwide.
BUILDING RATIONALLY DESIGNED AND OPTIMIZED IMMUNOTHERAPIES
Superior safety and efficacy can be obtained by engineering the sequence and 3-D shape of protein domains in order to stabilize specific structures of key sites in proteins. Our leading technology platform combines breakthroughs in antigen discovery and engineering with revolutionary nanoparticle-based formulation and delivery technologies. This allows us to create and develop unique 3D epitope-specific immunotherapies with a defined mode of action against virtually any protein target.
ADVANTAGES
- Avoidance of safety risks – No viral or animal material in process
- Target optimized immunogenicity, very low risk of unwanted immune-mediated disease enhancement
- Highly scalable & cost efficient processes
Registered Office in the U.S.:
- Shape Biopharmaceuticals Inc.
- 245 First St, Cambridge, MA 02142
- info@shapebiopharma.com
Registered Office in Switzerland:
- Shape Biopharmaceuticals GmbH
- Riedhofstrasse 11, 8804 Au ZH , Switzerland
- info@shapebiopharma.com